BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 17, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: WHO declares Ebola outbreak a public health emergency of international concernBreaking News: WHO declares Ebola outbreak a public health emergency of international concern
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

HIV-1 virus particle
HIV/AIDS

Düsseldorf patient cured of HIV after stem cell transplant

Feb. 20, 2023
By Mar de Miguel
Fifteen years ago, at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI), researchers announced that they had cured a patient – Timothy Ray Brown, initially known only as the Berlin Patient to preserve his privacy – of HIV through a hematopoietic stem cell transplant. Now, as researchers are gathered in Seattle for CROI 2023, reports of another cured patient were published Feb. 20, 2023, in Nature Medicine. Ten years after receiving a hematopoietic stem cell transplant, and 4 years after stopping antiretroviral treatment (ART), a 53-year-old patient may have been cured of HIV infection.
Read More
HIV/AIDS

Early in infection, HIV broadly targets CD4+ T cells to establish reservoir

Feb. 17, 2023
By Mar de Miguel
Results published Feb. 17, 2023, in Immunity have given a wider view of what happens in the earliest stages of HIV infection. Treatments against HIV prevent the replication of the virus, but do not kill the reservoir of latently infected cells that starts to build almost immediately upon infection.
Read More
Cancer

Medshine Discovery identifies new GSPT1-targeting PROTACs

Feb. 17, 2023
Medshine Discovery Inc. has presented heteroaryl-3-piperidinediones acting as proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety through linker.
Read More
Infection

Selmod divulges new antifungal compounds

Feb. 17, 2023
Selmod GmbH has identified compounds reported to be useful for the treatment of fungal infections.
Read More
Cancer

Carna Biosciences discovers new STING antagonists

Feb. 17, 2023
Carna Biosciences Inc. has synthesized 1,2-diaminobenzimidazole derivatives acting as stimulator of interferon genes protein (STING) antagonists reported to be useful for the treatment of cancer, viral infection, neurodegeneration and autoimmune, inflammatory, metabolic, eye and cardiovascular disorders, among others.
Read More
Neurology/Psychiatric

Astellas Pharma and Kotobuki Pharmaceutical patent new NLRP3 inflammasome inhibitors

Feb. 17, 2023
Astellas Pharma Inc. and Kotobuki Pharmaceutical Co. Ltd. have divulged annulated pyridazines...
Read More
Cancer

Neophore discloses new MLH1 and/or PMS2 inhibitors

Feb. 17, 2023
Neophore Ltd. has patented DNA mismatch repair protein Mlh1 (MLH1) and/or mismatch repair...
Read More
T cells attacking cancer cells
Immuno-oncology

SNX9 targeting: a promising strategy to prevent T-cell exhaustion and enhance antitumor immunity

Feb. 17, 2023
Tumor-specific CD8 T cells play a prominent role in antitumor immunity. However, these cells regularly enter a state of exhaustion due to chronic antigen stimulation within the tumor microenvironment.
Read More
Immuno-oncology

‘Trojan horse’ oncolytic vaccinia viruses expressing CD55 evade complement-mediated lysis

Feb. 17, 2023
Oncolytic virus immunotherapy has been proposed as a step forward for cancer treatment because it can kill cancer cells while activating the immune system. However, its current clinical application is limited because targeting deep-seated cancers is challenging and because the complement and innate immunity rapidly clear oncolytic viruses administered systemically.
Read More
Illustration of cancer cells entering the bloodstream.
Cancer

Nidogen-2 targeting reduces pancreatic cancer’s metastatic potential

Feb. 17, 2023
Pancreatic cancer still remains a highly lethal disease, with a 5-year survival rate of <10%. It is characterized by strong stromal activation leading to pro-tumorigenic extracellular matrix deposition. Recent findings in preclinical models have unveiled that targeting desmoplasia may improve chemotherapy efficacy and impede metastasis in pancreatic cancer.
Read More
Previous 1 2 … 1178 1179 1180 1181 1182 1183 1184 1185 1186 … 18070 18071 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • Illustration of tau accumulating in a neuron cell.

    Biogen AD drug shows tau, cognition benefit, despite trial miss

    BioWorld
    Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing